» Articles » PMID: 39941381

Cerebrospinal Fluid Biomarkers and Neuropsychological Abnormalities in Dementia: A Monocentric Study of Consecutive Patients

Overview
Journal J Clin Med
Specialty General Medicine
Date 2025 Feb 13
PMID 39941381
Authors
Affiliations
Soon will be listed here.
Abstract

: In search of indicators for dementia, this study investigated the association of cerebrospinal fluid (CSF) biomarkers and neuropsychological test results with disease stage in patients with early manifestations of dementia. : In 190 consecutive patients with symptoms of dementia, the CSF parameters amyloid-β 1-42 (Aβ1-42), phosphorylated tau protein (pTau), total tau protein (tTau), neuron-specific enolase (NSE), protein S100B (S100B), and Aβ (1-42)/(1-40) ratio (Aβ ratio), as well as the results of the CERAD-Plus test battery supplemented by the Clock Drawing Test (CDT), were analysed. Patients were divided into two groups based on the median duration of reported symptom onset. Most prominent in the early phase of the disease were the relationships between Aβ1-42 and neuropsychological memory subtests, which were absent in the later phase. Less pronounced relationships to memory function were detectable for Aβ ratio and pTau. The results substantiate the relevance of Aβ1-42 for memory deficits and support the amyloid cascade hypothesis for Alzheimer's dementia (AD). Our data suggest other pathomechanisms for visuospatial impairments in AD.

References
1.
Beach T, Monsell S, Phillips L, Kukull W . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012; 71(4):266-73. PMC: 3331862. DOI: 10.1097/NEN.0b013e31824b211b. View

2.
Spies P, Slats D, Sjogren J, Kremer B, Verhey F, Olde Rikkert M . The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res. 2010; 7(5):470-6. DOI: 10.2174/156720510791383796. View

3.
Boller F, Barba G . Neuropsychological tests in Alzheimer's disease. Aging (Milano). 2001; 13(3):210-20. DOI: 10.1007/BF03351479. View

4.
Yiannopoulou K, Papageorgiou S . Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis. 2020; 12:1179573520907397. PMC: 7050025. DOI: 10.1177/1179573520907397. View

5.
Sims J, Zimmer J, Evans C, Lu M, Ardayfio P, Sparks J . Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6):512-527. PMC: 10352931. DOI: 10.1001/jama.2023.13239. View